These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
422 related articles for article (PubMed ID: 26904917)
1. Hepatitis C virus and HIV seroprevalences, sociodemographic characteristics, behaviors and access to syringes among drug users, a comparison of geographical areas in France, ANRS-Coquelicot 2011 survey. Weill-Barillet L; Pillonel J; Semaille C; Léon L; Le Strat Y; Pascal X; Barin F; Jauffret-Roustide M Rev Epidemiol Sante Publique; 2016 Sep; 64(4):301-12. PubMed ID: 26904917 [TBL] [Abstract][Full Text] [Related]
2. High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011-14). Wenz B; Nielsen S; Gassowski M; Santos-Hövener C; Cai W; Ross RS; Bock CT; Ratsch BA; Kücherer C; Bannert N; Bremer V; Hamouda O; Marcus U; Zimmermann R; BMC Public Health; 2016 Sep; 16(1):927. PubMed ID: 27595567 [TBL] [Abstract][Full Text] [Related]
3. High regional variability of HIV, HCV and injecting risks among people who inject drugs in Poland: comparing a cross-sectional bio-behavioural study with case-based surveillance. Rosińska M; Sierosławski J; Wiessing L BMC Infect Dis; 2015 Feb; 15():83. PubMed ID: 25879904 [TBL] [Abstract][Full Text] [Related]
4. [Limited impact of the harm-reduction policy on HCV among drug-users. The ANRS-Coquelicot survey example]. Jauffret-Roustide M; Emmanuelli J; Desenclos JC Rev Epidemiol Sante Publique; 2006 Jul; 54 Spec No 1():1S53-1S59. PubMed ID: 17073130 [TBL] [Abstract][Full Text] [Related]
5. [Drug Consumption Rooms : Opinion and willingness among people who inject drugs in Marseille, France]. Briand Madrid L; Donadille C; Célerier I; Gutowski M; Grelli N; Maradan G; Jauffret-Roustide M; Lalanne L; Auriacombe M; Roux P; Rev Epidemiol Sante Publique; 2023 Feb; 71(1):101421. PubMed ID: 36571957 [TBL] [Abstract][Full Text] [Related]
6. Alarming epidemics of human immunodeficiency virus and hepatitis C virus among injection drug users in the northwestern bordering state of Punjab, India: prevalence and correlates. Panda S; Roy T; Pahari S; Mehraa J; Sharma N; Singh G; Singh J; Joseph F; Singh S; Sharma NM Int J STD AIDS; 2014 Jul; 25(8):596-606. PubMed ID: 24352120 [TBL] [Abstract][Full Text] [Related]
7. Prevalence and behavioural risks for HIV and HCV infections in a population of drug users of Dakar, Senegal: the ANRS 12243 UDSEN study. Leprêtre A; Ba I; Lacombe K; Maynart M; Toufik A; Ndiaye O; Kane CT; Gozlan J; Tine J; Ndoye I; Raguin G; Girard PM J Int AIDS Soc; 2015; 18(1):19888. PubMed ID: 26004637 [TBL] [Abstract][Full Text] [Related]
8. Impact of a harm-reduction policy on HIV and hepatitis C virus transmission among drug users: recent French data--the ANRS-Coquelicot Study. Jauffret-Roustide M; Emmanuelli J; Quaglia M; Barin F; Arduin P; Laporte A; Desenclos JC Subst Use Misuse; 2006; 41(10-12):1603-21. PubMed ID: 17002994 [TBL] [Abstract][Full Text] [Related]
9. HIV infection and risk, prevention, and testing behaviors among injecting drug users -- National HIV Behavioral Surveillance System, 20 U.S. cities, 2009. Broz D; Wejnert C; Pham HT; DiNenno E; Heffelfinger JD; Cribbin M; Krishna N; Teshale EH; Paz-Bailey G; MMWR Surveill Summ; 2014 Jul; 63(6):1-51. PubMed ID: 24990587 [TBL] [Abstract][Full Text] [Related]
10. Impact of drug consumption rooms on risk practices and access to care in people who inject drugs in France: the COSINUS prospective cohort study protocol. Auriacombe M; Roux P; Briand Madrid L; Kirchherr S; Kervran C; Chauvin C; Gutowski M; Denis C; Carrieri MP; Lalanne L; Jauffret-Roustide M; BMJ Open; 2019 Feb; 9(2):e023683. PubMed ID: 30796121 [TBL] [Abstract][Full Text] [Related]
11. Migration experiences, life conditions, and drug use practices of Russian-speaking drug users who live in Paris: a mixed-method analysis from the ANRS-Coquelicot study. Tibi-Lévy Y; Serebryakova D; Jauffret-Roustide M; Harm Reduct J; 2020 Aug; 17(1):55. PubMed ID: 32778108 [TBL] [Abstract][Full Text] [Related]
12. High prevalence of HIV, HBsAg and anti-HCV positivity among people who injected drugs: results of the first bio-behavioral survey using respondent-driven sampling in two urban areas in Mozambique. Semá Baltazar C; Horth R; Boothe M; Sathane I; Young P; Chitsondzo Langa D; Condula M; Ricardo H; Dengo Baloi L; Cummings B; Schaad N; Gouveia L; Teodoro E; Raymond HF BMC Infect Dis; 2019 Dec; 19(1):1022. PubMed ID: 31791273 [TBL] [Abstract][Full Text] [Related]
13. Change in HIV-HCV risk-taking behavior and seroprevalence among opiate users seeking treatment over an 11-year period and harm reduction policy. Fatseas M; Denis C; Serre F; Dubernet J; Daulouède JP; Auriacombe M AIDS Behav; 2012 Oct; 16(7):2082-90. PubMed ID: 21983799 [TBL] [Abstract][Full Text] [Related]
14. Drug consumption rooms are effective to reduce at-risk practices associated with HIV/HCV infections among people who inject drugs: Results from the COSINUS cohort study. Lalanne L; Roux P; Donadille C; Briand Madrid L; Célerier I; Chauvin C; Hamelin N; Kervran C; Maradan G; Auriacombe M; Jauffret-Roustide M; Addiction; 2024 Jan; 119(1):180-199. PubMed ID: 37743675 [TBL] [Abstract][Full Text] [Related]
15. Seroprevalence of HCV and HIV infection among clients of the nation's longest-standing statewide syringe exchange program: A cross-sectional study of Community Health Outreach Work to Prevent AIDS (CHOW). Salek TP; Katz AR; Lenze SM; Lusk HM; Li D; Des Jarlais DC Int J Drug Policy; 2017 Oct; 48():34-43. PubMed ID: 28779632 [TBL] [Abstract][Full Text] [Related]
16. Drug consumption rooms in Catalonia: A comprehensive evaluation of social, health and harm reduction benefits. Folch C; Lorente N; Majó X; Parés-Badell O; Roca X; Brugal T; Roux P; Carrieri P; Colom J; Casabona J; Int J Drug Policy; 2018 Dec; 62():24-29. PubMed ID: 30352331 [TBL] [Abstract][Full Text] [Related]
17. Risk behaviours and viral infections among drug injecting migrants from the former Soviet Union in Germany: Results from the DRUCK-study. Derks L; Gassowski M; Nielsen S; An der Heiden M; Bannert N; Bock CT; Bremer V; Kücherer C; Ross S; Wenz B; Marcus U; Zimmermann R; Int J Drug Policy; 2018 Sep; 59():54-62. PubMed ID: 30005420 [TBL] [Abstract][Full Text] [Related]
18. Prevalence and risk factors of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infections among drug addicts in Bangladesh. Shirin T; Ahmed T; Iqbal A; Islam M; Islam MN J Health Popul Nutr; 2000 Dec; 18(3):145-50. PubMed ID: 11262767 [TBL] [Abstract][Full Text] [Related]
19. Characteristics associated with HIV and hepatitis C seroprevalence among sexual and injecting partners of HIV positive persons who inject drugs in Nairobi and coastal Kenya. Sambai BC; Kingston H; Monroe-Wise A; Mbogo L; Juma E; Ludwig-Barron N; Guthrie BL; Bukusi D; Chohan BH; Scott J; Bosire R; Dunbar M; Macharia P; Masyuko S; Sinkele W; Herbeck JT; Farquhar C BMC Infect Dis; 2022 Jan; 22(1):73. PubMed ID: 35062890 [TBL] [Abstract][Full Text] [Related]
20. High hepatitis C virus prevalence and incidence in a community cohort of young heroin injectors in a context of extensive harm reduction programmes. Vallejo F; Barrio G; Brugal MT; Pulido J; Toro C; Sordo L; Espelt A; Bravo MJ; J Epidemiol Community Health; 2015 Jun; 69(6):599-603. PubMed ID: 25870164 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]